Lymphangitis secondary prevention

Revision as of 21:48, 2 June 2014 by Vendhan Ramanujam (talk | contribs) (Created page with "__NOTOC__ {{Lymphangitis}} {{CMG}}; {{AE}} {{VR}} ==Overview== Lymphangitis is most often caused by recurrent skin infections due to Streptococcus pyogenes|group A beta-he...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Lymphangitis Microchapters

Home

Overview

Historical Perspective

Classification

Causes

Pathophysiology

Differentiating Lymphangitis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Case Studies

Case #1

Lymphangitis secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Lymphangitis secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Lymphangitis secondary prevention

CDC on Lymphangitis secondary prevention

Lymphangitis secondary prevention in the news

Blogs on Lymphangitis secondary prevention

Directions to Hospitals Treating Lymphangitis

Risk calculators and risk factors for Lymphangitis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vendhan Ramanujam M.B.B.S [2]

Overview

Lymphangitis is most often caused by recurrent skin infections due to group A beta-hemolytic streptococci and prophylactic administration of antibiotics can reduce the risk of these skin infections complicating into lymphangitis.

Secondary Prevention

Most of recurrent cellulitis is caused by group A beta-hemolytic streptococci, thus monthly administration of 1.2 MU of intramuscular benzathine penicillin or 250 mg of oral erythromycin or 1 g of penicillin V in adults can reduce the risk of development of lymphangitis.[1]

References

  1. Moran GJ, Abrahamian FM, Lovecchio F, Talan DA (2013). "Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines". J Emerg Med. 44 (6): e397–412. doi:10.1016/j.jemermed.2012.11.050. PMID 23466022.

Template:WH Template:WS